Researchers found that most genes affecting drugresponses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.
Liver problems may reduce the effectiveness of oral minoxidil due to impaired SULT1A1 enzyme activity, which is crucial for converting minoxidil to its active form. This reduction in enzyme function can significantly decrease the drug's effectiveness in promoting hair growth.
The conversation is about the effectiveness of hair loss treatments, specifically finasteride and dutasteride, in different populations. Some users believe that the results of Japanese studies may not be relevant to Caucasian men, especially young ones, and that East Asians may respond better to these treatments. Others argue that clinical studies should be the basis for decision-making, while acknowledging that individual responses to medications can vary.
Finasteride and dutasteride can show initial hair count increases within 12 weeks, but visible improvements often take longer, with many users reporting noticeable changes after a year or more. While early results may be seen under a microscope, significant cosmetic improvements typically require more time for hair to thicken and become visibly denser.
Finasteride may cause hair shedding as part of the regrowth process, but there are no controlled trials confirming this. The shedding idea is mostly based on anecdotal reports and comparisons to how minoxidil works.